Your browser doesn't support javascript.
loading
Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature.
Lodi, Mariachiara; Boccuto, Luigi; Carai, Andrea; Cacchione, Antonella; Miele, Evelina; Colafati, Giovanna Stefania; Diomedi Camassei, Francesca; De Palma, Luca; De Benedictis, Alessandro; Ferretti, Elisabetta; Catanzaro, Giuseppina; Pò, Agnese; De Luca, Alessandro; Rinelli, Martina; Lepri, Francesca Romana; Agolini, Emanuele; Tartaglia, Marco; Locatelli, Franco; Mastronuzzi, Angela.
Afiliação
  • Lodi M; Department of Paediatric Haematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Boccuto L; School of Nursing, College of Behavioral, Social and Health Sciences, Clemson University, Clemson, SC 29634, USA.
  • Carai A; JC Self Research Institute of the Greenwood Genetic Center, Greenwood, SC 29646, USA.
  • Cacchione A; Neurosurgery Unit, Department of Neuroscience and Neurorehabilitation, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Miele E; Department of Paediatric Haematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Colafati GS; Department of Paediatric Haematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Diomedi Camassei F; Neuroradiology Unit, Department of Imaging, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • De Palma L; Department of Laboratories, Pathology Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • De Benedictis A; Neurology Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Ferretti E; Neurosurgery Unit, Department of Neuroscience and Neurorehabilitation, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Catanzaro G; Neurology Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Pò A; Department of Experimental Medicine, Sapienza University, 00161 Rome, Italy.
  • De Luca A; Department of Molecular Medicine, Sapienza University, 00161 Rome, Italy.
  • Rinelli M; Medical Genetics Division, Fondazione IRCCS-Casa Sollievo della Sofferenza, 71043 San Giovanni Rotondo, Italy.
  • Lepri FR; Laboratory of Medical Genetics, Department of Laboratories, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Agolini E; Laboratory of Medical Genetics, Department of Laboratories, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Tartaglia M; Laboratory of Medical Genetics, Department of Laboratories, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Locatelli F; Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Mastronuzzi A; Department of Paediatric Haematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Diagnostics (Basel) ; 10(8)2020 Aug 12.
Article em En | MEDLINE | ID: mdl-32806529
ABSTRACT
Noonan syndrome (NS) is a congenital autosomic dominant condition characterized by a variable spectrum from a clinical and genetical point of view. Germline mutations in more than ten genes involved in RAS-MAPK signal pathway have been demonstrated to cause the disease. An higher risk for leukemia and solid malignancies, including brain tumors, is related to NS. A review of the published literature concerning low grade gliomas (LGGs) in NS is presented. We described also a 13-year-old girl with NS associated with a recurrent mutation in PTPN11, who developed three different types of brain tumors, i.e., an optic pathway glioma, a glioneuronal neoplasm of the left temporal lobe and a cerebellar pilocytic astrocytoma. Molecular characterization of the glioneuronal tumor allowed to detect high levels of phosphorylated MTOR (pMTOR); therefore, a therapeutic approach based on an mTOR inhibitor (everolimus) was elected. The treatment was well tolerated and proved to be effective, leading to a stabilization of the tumor, which was surgical removed. The positive outcome of the present case suggests considering this approach for patients with RASopathies and brain tumors with hyperactivated MTOR signaling.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article